Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

pembrolizumab 1034Carboplatin 973Paclitaxel 942Gemcitabine 799Cisplatin 759Docetaxel 699Bevacizumab 637Nivolumab 520Pemetrexed 509Cyclophosphamide 476Capecitabine 475Fluorouracil 425Dexamethasone 410Rituximab 392Oxaliplatin 352Injections 349Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 252Ipilimumab 244Doxorubicin 242Lenalidomide 231Fulvestrant 226fludarabine 221durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × MAC-ST-001 × Clear all
NCT06922539 2025-12-15

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

SciTech Development, Inc.

Phase 1 Recruiting
44 enrolled
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT04234048 2025-09-22

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

SciTech Development, Inc.

Phase 1 Recruiting
46 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡